Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study
Open Access
- 4 January 2007
- journal article
- research article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 7 (3), 560-570
- https://doi.org/10.1111/j.1600-6143.2006.01645.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ, 2005
- Five preventable causes of kidney graft loss in the 1990s: A single-center analysis1Kidney International, 2002
- Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy: A Randomized, Prospective, Multicenter StudyJournal of the American Society of Nephrology, 2002
- Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysisTransplant International, 2000
- Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysisTransplant International, 2000
- REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1Transplantation, 1999
- LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2Transplantation, 1998
- MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITYTransplantation, 1998
- HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATIONTransplantation, 1997
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976